Cabaletta Bio to Participate in Upcoming Investor Conferences
Key Highlights
- ➤Cabaletta Bio to present at Guggenheim healthcare conference November 10, 2026
- ➤Cabaletta Bio to present at Jefferies Global Healthcare Conference November 18, 2026
- ➤Rese-cel is an investigational 4-1BB-containing fully human CD19-CAR T therapy
- ➤RESET program spans rheumatology, neurology, and dermatology autoimmune indications
PHILADELPHIA, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced its participation in the following upcoming investor conferences: * Guggenheim’s 3rd Annual Healthcare Innovation Conference: Meetings with investors and a webcasted fireside chat at 9:00 a.m. ET on Tuesday, November 10, 2026, in Boston, MA.
* 2026 Jefferies Global Healthcare Conference in London: Meetings with investors and a webcasted fireside chat at 5:00 p.m. GMT (12:00 p.m. ET) on Wednesday, November 18, 2026, in London, UK. The webcasted fireside chats will be accessible on the News and Events section of the Company’s website at www.cabalettabio.com. Archived replays will be available for 30 days.
Get started
Create a free account to read the full story.